Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure

Table 3 Treatment compliance during chemoradiotherapy and systemic chemotherapy, n (%)

	Standard therapy during CRT	TNT	P value
Patients who received CRT	72 (100)	88 (99)	0.2751
Patients who received RT	0 (0)	1 (1)
Full-dose ChT (CAP or 5-FU + LV)	62 (86)	67 (75)	0.087
Modification of concomitant ChT	10 (14)	22 (25)
Modification of RT	1 (1)	0 (0)
	During adjuvant ChT	During systemic ChT
Without ChT due to pCR	5 (7)	0 (0)
Patients who received ChT	50 (72)	89 (100)
All planned cycle
6c of systemic ChT (CAP or CAPOX)	34 (68)	76 (85)	0.0481
Other alternative schemes	4 (8)	2 (2)
No	12 (24)	11 (12)
Full-dose
6c of systemic ChT (CAP or CAPOX)	25 (50)	56 (63)	0.1581
Other alternative schemes	4 (8)	2 (2)
No	21 (42)	31 (35)

¹Likelihood-ratio test.

5-FU: 5-fluorouracil; c: Cycle; CAP: Capecitabine; CAPOX: Capecitabine and oxaliplatin; ChT: Chemotherapy; CRT: Chemoradiotherapy; LV: Leucovorin; pCR: Pathological complete response; RT: Radiotherapy; TNT: Total neoadjuvant treatment.